SR One, the venture capital arm of GlaxoSmithKline, focuses on investing in innovative life science companies globally. The firm primarily targets Series A and Series B funding rounds, with additional investments in later stages such as Series C and D. SR One's investment strategy is centered on backing companies with strong fundamentals and novel approaches to addressing diseases, aiming to translate cutting-edge science into transformative medical treatments.

Notable portfolio companies include Adarx Pharmaceuticals, Avalyn Pharma, Nimbus Therapeutics, and Odyssey Therapeutics. The firm is led by experienced partners who bring a wealth of industry expertise and connections, enhancing their ability to support portfolio companies beyond capital investment. SR One offers a unique "back-and-build" approach, providing strategic guidance and leveraging its extensive network to help startups navigate the complexities of drug development and commercialization.